IMMUNOCORE HOLDINGS PL

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

20 سبتمبر 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

13 سبتمبر 2021 15:30:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

10 سبتمبر 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

08 سبتمبر 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

24 أغسطس 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

11 أغسطس 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

04 يونيو 2021 08:05:00 بحسب Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

27 مايو 2021 15:30:00 بحسب Nasdaq GlobeNewswire

Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B

18 مايو 2021 15:10:00 بحسب Nasdaq GlobeNewswire

Immunocore Reports First Quarter 2021 Financial Results

12 مايو 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

28 أبريل 2021 15:30:00 بحسب Nasdaq GlobeNewswire

Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting

12 أبريل 2021 15:30:00 بحسب Nasdaq GlobeNewswire

Immunocore Provides Business Update and Reports Full Year 2020 Financial Results

25 مارس 2021 06:00:00 بحسب Nasdaq GlobeNewswire

Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting

10 مارس 2021 18:00:00 بحسب Nasdaq GlobeNewswire

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

19 فبراير 2021 06:00:00 بحسب Nasdaq GlobeNewswire